WO2023217744 - PRODRUGS OF GLP-1 POLYPEPTIDE AND USES THEREOF
National phase entry:
Publication Number
WO/2023/217744
Publication Date
16.11.2023
International Application No.
PCT/EP2023/062208
International Filing Date
09.05.2023
Title **
[English]
PRODRUGS OF GLP-1 POLYPEPTIDE AND USES THEREOF
[French]
PROMÉDICAMENTS DE POLYPEPTIDE GLP-1 ET LEURS UTILISATIONS
Applicants **
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd, DK
Inventors
PREMDJEE, Bhavesh
Novo Alle 1
2880 Bagsværd, DK
LAU, Jesper F.
Novo Alle 1
2880 Bagsværd, DK
JØRGENSEN, Cecilie Mia
Novo Alle 1
2880 Bagsværd, DK
LYKKE, Lennart
Novo Alle 1
2880 Bagsværd, DK
Priority Data
22172545.0
10.05.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1242 | |
| EPO | Filing, Examination | 5177 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 10295 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to DKP-based prodrugs from which a parent drug, such as semaglutide, is liberated upon conversion of the prodrug under in-vivo conditions. The invention also relates to the use of DKP-based prodrugs.[French]
L'invention concerne des promédicaments à base de DKP à partir desquels un médicament parent, tel que le sémaglutide, est libéré après conversion du promédicament dans des conditions in vivo. L'invention concerne également l'utilisation de promédicaments à base de DKP.